Androgen deprivation therapy is a cornerstone in the treatment of advanced prostate cancer and has extended the lives of countless patients. Unfortunately, many of these patients eventually succumb to metastatic castration-resistant prostate cancer (mCRPC). The efficacy of abiraterone acetate (AA, Zytiga) and enzalutamide (Enza, Xtandi) in the mCRPC setting prove that these tumors remain androgen-driven. We review recent studies that have shown that intratumoral androgen biosynthesis plays a significant role in the ever-evolving mCRPC tumor and we discuss the therapeutic implications of these findings.
INTRODUCTION
The legacy of Huggins and Hodges' landmark discovery of the use of surgical castration or orchiectomy and adrenalectomy to treat advanced prostate cancer continues to this day. Androgen deprivation is achieved in the clinic using first-line therapies, such as leuprolide (a luteinizing hormone releasing hormone agonist), R-bicalutamide (an androgen receptor antagonist), and dutasteride (dual 5a-reductase type 1 and type 2 inhibitor). Second-line therapies include abiraterone acetate (AA), which inhibits cytochrome P450 17ahydroxylase, 17,20-lyase (P450c17) in the adrenal glands and in the tumor, and enzalutamide (Enza), which acts as an androgen receptor super antagonist, inhibits androgen receptor translocation to the nucleus, and increases androgen receptor degradation. New agents are in development and include the cytochrome P450 17,20-lyase specific inhibitor, 17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3b-ol) also known as galeterone (TOK-001) [1 & ] and the next-generation androgen receptor antagonists, such as 4-[7-[6-Cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro [3, 4] octan-5-yl]-2-fluoro-N-methylbenzamide also known as apalutamide (ARN-509) [2] , the nonsteroidal AR antagonist, N((R)-1- (3- . The growing number of therapeutic choices has led to the question of the sequence with which to administer the therapies and the need for robust biomarkers to personalize treatment regimens. Perhaps the most pressing issue in prostate cancer is the need to surmount castration resistance, drug resistance, or the combination of the two.
The underlying biology that drives metastatic castration-resistant prostate cancer (mCRPC) progression is complex. As the field elucidates the mechanisms that underpin mCRPC, the treatment regimen can be personalized to the individual by validating and using biomarkers to guide the decision as to which drug to administer to increase patient survival. For example, the androgen receptor splice variant, AR-V7, is an area of intense interest. The ligand-binding domain is deleted in AR-V7, resulting in a constitutively active androgen receptor. The dynamics of the emergence of AR-V7 in circulating tumor cells (CTCs) is of particular interest [12 & ] as it may be predictive of nonresponders to abiraterone acetate and Enza. Therefore, AR-V7 positive patients may be candidates for radiation or taxane treatment [13 & ], whereas AR-V7 negative patients may be treated with ADT. However, the AR-V7 does not account for all of the nonresponding tumors and there is abundant evidence to suggest that aberrations in the prereceptor biology may also be a mechanism underlying progression to mCRPC and drug resistance [14
Here, we highlight recent studies that have interrogated the prereceptor biology and give insight into putative therapeutic targets for mCRPC. The first study examines the properties of D4A, a novel metabolite of abiraterone that results from its metabolism via 3bhydroxysteroid dehydrogenase (3b-HSD) type 1. Then, we examine two recent studies that have added to the body of work on the significant role that the androgen biosynthetic enzyme aldo-keto reductase 1C3 (AKR1C3), also known as 17b-hydroxysteroid dehydrogenase type 5, plays in mCRPC biology.
TEXT OF REVIEW
The second-line ADT therapies, abiraterone acetate and Enza, are clinically approved for use in the mCRPC setting. Abiraterone acetate has extended the lives of patients who have progressed after ADT and docetaxel treatment by a median of 1-2 months [17]. This finding was significant because it established that mCRPC tumors remain androgendriven. However, the clinical experience has shown that the tumor ultimately evolves to become resistant to abiraterone acetate. Clinical studies have shown the efficacy of abiraterone acetate in the neoadjuvant space and this may improve outcomes [18 & ]. Enza has also been shown to extend median survival in the post-ADT and postdocetaxel mCRPC space by a median of 1-2 months [19] and was found to significantly improve survival relative to
Here, we critically review several topical studies on the role of androgen metabolism in mCRPC biology and the ramifications of their findings on the treatment of mCRPC.
D4A, a novel metabolite of abiraterone acetate
In a study by Li and colleagues [22 && ], abiraterone was found to be a substrate for metabolism by 3b-HSD type 1 to form a D 4 -3-ketosteroid metabolite of abiraterone, which was referred to as D4A. This novel metabolite is of minor abundance in human patient serum, comprising on average, approximately 4% of total abiraterone acetate after a 1000 mg dose. The inhibition of P450c17 and 3b-HSD1 by D4A is comparable to that seen with abiraterone. This raises the question as to whether abiraterone acts as an inhibitor of 3b-HSD1 or KEY POINTS 3b-HSD1 metabolizes abiraterone to D4A, its D 4 -3ketosteroid metabolite, which acts as an androgen receptor antagonist.
The TMPRSS2 : ERG gene fusion up-regulates AKR1C3 in a feed-forward manner.
Inhibition of AKR1C3 surmounts Enza drug resistance.
Intratumoral androgen metabolism plays a significant role in a subpopulation of mCRPC tumors, and enzymes downstream from P450c17 are targets for drug development.
whether it exerts its effect after conversion to the D4A metabolite. D4A was also found to inhibit 5a-reductase activity, whereas abiraterone did not. Furthermore, D4A was found to have increased antagonism toward the androgen receptor relative to abiraterone (Fig. 1 ). In LNCaP cells, D4A inhibited gene expression of prostate specific antigen (PSA), TMPRSS2, and FK506 binding protein (cis-transprolyl isomerase) (FKBP5) upon stimulation with dehydroepiandrosterone (DHEA), 5a-dihydrotestosterone (DHT), and methyltrienolone (R1881). These findings indicate that the D4A metabolite is bifunctional and mediates its effects by inhibition of androgen biosynthesis and by androgen receptor antagonism. D4A inhibited DHT-induced proliferation of LNCaP cells. In LNCaP or VCaP xenografts in the immuno-deficient NSG mouse, the adrenal glands express 3bHSD-1 and were thus the site at which D4A was produced, that is D4A was not produced in the mouse prostate tissue. The study also showed that D4A exhibited improved progression-free survival in both VCaP and C4-2 rodent xenograft models relative to AA. In the VCaP xenograft model, D4A inhibited growth significantly better than abiraterone acetate at 3 days (P < 0.01) and at 9 days (P < 0.05) [22 && ]. These findings present a case for the administration of the D4A metabolite in prostate cancer therapy. The main advantage of the D4A compound as highlighted by the molecular studies is the added benefit of 5a-reductase inhibition and androgen receptor antagonism. The efficacy of D4A was well characterized by Li and colleagues using a variety of approaches. It is of interest that much of the molecular work was done in the LNCaP cell line and the rodent xenograft model employed the VCaP and C4-2 cell lines. The LNCaP cell line has a mutated androgen receptor (T877A), suggesting that D4A can also antagonize the mutant androgen receptor. Thus far, the D4A metabolite has yet to be screened as a ligand for other steroid receptors or tested for efficacy in patient derived xenografts. On a broader level, the findings present a paradox, whereby previous findings by Chang and colleagues [23] showed that the N376T mutant of 3b-HSD1 facilitated the stabilization of the protein and biosynthesis of DHT in the mCRPC tumor and was therefore postulated to be a poor prognostic indicator. In light of this study, patients with the N376T mutant tumors should be expected to generate more D4A metabolite intratumorally and patients harboring this mutation should have an improved response to abiraterone.
The ERG/aldo-keto reductase 1C3/androgen receptor androgen axis
In prostate cancer, the TMPRSS2 : ERG gene fusion has been shown to be overexpressed in higher Gleason grade disease and at metastatic sites. However, the exact role of ERG has not been clearly examined. In a study by Powell and colleagues [24 && ], VCaP cells were used to establish a lentiviral shRNA knockdown of ERG. In the VCaP shERG knockdown cells, transcripts of AKR1C3, HSD17B6, and HSD17B4 were significantly reduced relative to the VCaP-shscrambled control. This correlation was also seen with AKR1C3 protein expression levels. In LNCaP and BPH-1 cells, the overexpression of ERG-40 (a truncated version of ERG lacking the first 39 amino acids on the N-terminus) resulted in the up-regulation of AKR1C3 expression. Chromatin immuno-precipitation sequencing (ChIP-seq) data of VCaP cells identified two binding peaks far upstream of the transcriptional start site in the AKR1C3 gene, one at $50 kb, one at $75 kb and another one in intron 1. In VCaP-shERG cells, the conversion of 5a-androstane-3,17-dione (Adione) to DHT was reduced by $80% relative to the VCaP-shscrambled control. VCaP cells supplemented with Adione led to the translocation of the androgen receptor and stimulated PSA expression. However, PSA expression was diminished in VCaP-shERG and VCaP-shAKR1C3 relative to controls (Fig. 2) . The study used bioinformatics to probe the relationship between ERG and AKR1C3 in patient samples. In a cohort of 64 patients, 24 were ERG þ /AKR1C3 þ and 25 were ERG -/AKR1C3 À . Furthermore, Oncomine, which is a cancer microarray database and data mining platform (http://www.oncomine.org) was used to query for TMPRSS2 : ERG and AKR1C3 expression in prostate cancer tumors and generate Kaplan-Meier curves. This analysis showed poorer survival for prostate cancer patients with tumors that had TMPRSS2 : ERG þ /high AKR1C3 expressing tumors relative to patients that had TMPRSS2 : ERG À /low AKR1C3 expressing tumors [24
&&
].
The study shows that ERG exerts regulatory control over the expression and activity of AKR1C3, 17b-HSD6, and 17b-HSD4. 17b-HSD4 is an NAD þdependent dehydrogenase that inactivates T and DHT by converting them to D 4 -AD and Adione, respectively [25] . The regulation of 17b-HSD6 is extremely interesting in the context of intratumoral androgen metabolism as it is the predominant 3a-HSD responsible for the conversion of 3a-Adiol to DHT via the 'backdoor pathway' [26] . Moreover, in VCaP shERG knockdown cells, a decreased conversion of Adione to DHT by AKR1C3 and diminished downstream androgen receptor translocation and PSA expression were observed. These findings strongly support an ERG/AKR1C3/androgen receptor feed-forward signaling mechanism. In this mechanism, TMPRSS2 : ERG is expressed in advanced disease, overriding the repressive effect of androgen receptor on the AKR1C3 promoter. Increased production of T and DHT by AKR1C3 induces TMPRSS2 : ERG, leading to the feed-forward up-regulation of AKR1C3. The bioinformatics work also displays a correlation between ERG and AKR1C3 expression in patient samples. Furthermore, patient prognosis is worse in patients that are positive for the TMPRSS2 : ERG gene fusion and have elevated AKR1C3 expression, relative to those that do not possess the gene fusion and have low AKR1C3 expression. This would seem to be at odds with recent clinical studies which have found that the TMPRSS2 : ERG gene fusion predicts for tumors that are more responsive to ADT, though these studies did not look at AKR1C3 expression
Intracrine androgens and aldo-keto reductase 1C3 confers resistance to enzalutamide
The androgen receptor super-antagonist, Enza, has become one of the mainstays in the clinician's ADT tool kit. Unfortunately, resistance to Enza is a significant problem that ultimately results in patient death. Liu and colleagues [29 && ] developed an Enzaresistant subline of the C4-2B cell line after serial exposure to the drug. They called this subline, C4-2B MDVR. The C4-2B MDVR cells were more resistant to enzalutamide relative to the parental C4-2B cells in an orthotopic SCID mouse. The transcript level and protein expression of androgen biosynthetic enzymes, such as 3b-HSD1, AKR1C3, and P450c17 were up-regulated in the C4-2B MDVR cells relative to the parental C4-2B cells (Fig. 3 ). AKR1C3 protein expression levels were measured in a panel of prostate cancer cell lines and were as follows: VCaP > CWR22Rv1 > C4-2B MDVR > LN-95 > LNCaP > C4-2B. Using Oncomine, the study found AKR1C3 to be low in benign prostate and primary prostate cancer and elevated in metastatic Current advances in intratumoral androgen metabolism Penning and Tamae prostate cancer. Furthermore, the Oncomine data showed that AKR1C3 expression levels correlate with Gleason score and recurrence. Quantification of select androgens showed that T, DHT, and DHEA were higher in C4-2B MDVR cells vs. C4-2B cells. Knockdown of AKR1C3 in the C4-2B MDVR and CWR22Rv1 cell lines sensitized these cells to Enza treatment. When the converse approach was used and AKR1C3 was over-expressed in LNCaP cells, this conferred resistance to Enza relative to the parental LNCaP cells. The NSAID, indomethacin, is a potent and selective AKR1C3 inhibitor identified by our lab [30] , and was used alone and in combination with Enza in this study. In clonogenic assays with C4-2B MDVR and CWR22Rv1 cells, the combination of indomethacin and Enza reduced colony formation by $70-80%, with the more pronounced effect in C4-2B MDVR cells compared with CWR22Rv1 cells.
In the CWR22Rv1 xenograft model, indomethacin alone had a more pronounced effect on tumor volume reduction compared with Enza alone. The most robust response in tumor volume reduction and Ki67 staining came from the combination of indomethacin and Enza [29 && ]. The study shows for the first time that AKR1C3 along with several other androgen biosynthetic enzymes are overexpressed as a result of long-term Enza treatment of the C4-2B prostate cancer cell line. The C4-2B MDVR cells were sensitized to Enza using indomethacin in clonogenic assays and in a xenograft model using the CWR22Rv1 cell line; pointing the way to how Enza resistance may be treated clinically. The data provides a compelling case that AKR1C3 may be a therapeutic target in Enza-resistant mCRPC.
Targeting intratumoral androgen metabolism in castration-resistant prostate cancer
Improving the survival of mCRPC patients is an area of unmet need and tremendous opportunity. The second-line therapies, abiraterone acetate and Enza have extended the survival in many patients that become refractory to first-line therapies. However, the eventual emergence of abiraterone acetate or Enza-resistance still claims the lives of the vast majority of these patients. The administration of these drugs in the neoadjuvant setting [18 & ] and the up-front combination of ADT with taxanes [9 & ] has begun to yield improved results. Indeed, clinical evidence is beginning to emerge that suggests that more intense and continuous androgen deprivation correlates with improved outcomes [31 & ]. The interrogation of the alterations in androgen biosynthetic enzymes that occur in the tumor during progression to mCRPC have given us insight into putative therapeutic targets. The discovery and characterization of the D4A metabolite by Li and colleagues [22 && ] is of interest as it dovetails with the data from Liu and colleagues [29 && ], which found that long-term Enza treatment resulted in the up-regulation of a panel of androgen biosynthetic enzymes including AKR1C3, 3b-HSD1, and P450c17. The two studies taken together would suggest that a subpopulation of Enza-resistant patients that have not yet been treated with abiraterone acetate may overexpress 3b-HSD1, which would generate the D4A metabolite intratumorally and may be patients who stand to benefit from abiraterone acetate therapy. These tumors may also be candidates for AKR1C3 inhibition. AKR1C3 is overexpressed in prostate tumors relative to normal prostate tissue and in response to ADT. Castration of a VCaP orthotopic model has been found to lead to the up-regulation of steroidogenic enzymes, including AKR1C3 [32 & ]. Our lab has been at the forefront in elucidating the role of AKR1C3 in prostate cancer [33] . We have developed lead drug candidates for the specific inhibition of AKR1C3 over the AKR1C1 and AKR1C2 isoforms whose activity is desirable because they inactivate the potent androgen receptor ligand, DHT [34,35 & ]. Our work with clinical collaborators has yielded data from the neoadjuvant leuprolide/abiraterone acetate clinical trial that supports the hypothesis that the DHEA sulfate depot that remains post-abiraterone acetate may feed intratumoral androgen biosynthesis. As AKR1C3 is one of the most overexpressed steroidogenic genes in CRPC, its presence plus the DHEA sulfate pool could create a perfect storm for abiraterone acetate resistance [36 & ]. Thus, inhibition of AKR1C3 would be desirable. Although the role of AKR1C3 in intratumoral androgen biosynthesis is a primary focus with regards to prostate cancer, the inhibition of AKR1C3 may also exert beneficial antiproliferative effects via inhibition of either its prostaglandin F synthase activity or its androgen receptor coactivator function or its role in regulating androgen receptor transcriptional activity via the inhibition of SIAH2 self-ubiquitination [37,38,39 & ]. Furthermore, the metastases of prostate cancer to the bone may be facilitated by the overexpression of AKR1C3 among other steroidogenic enzymes [40 & ].
CONCLUSION
The treatment of prostate cancer has evolved considerably since the days of Huggins and Hodges and patient outcomes have improved. However, the emergence of mCRPC and drug resistance is the biggest hurdle to improving patient survival. Androgen biosynthetic enzymes play an integral role in the mCRPC tumor and in an Enza resistance model. This sets up a potential therapeutic strategy of targeting these key players such as AKR1C3 to resensitize these tumors to the current ADT armamentarium.
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